AdiaVita + Glutathione for Chronic Kidney Disease

This trial explores a new treatment for adults with chronic kidney disease (CKD) to determine if it can safely improve kidney function. The treatment, called AdiaVita, combines stem cells and exosomes from umbilical cord blood with glutathione. Researchers will compare participants across three groups: one receiving the full treatment, another receiving glutathione plus a placebo, and a third receiving placebos for both. Individuals with CKD who are not on dialysis and can attend regular clinic visits may be suitable for this trial. Researchers will closely monitor safety throughout the study to ensure the treatment's safety for participants. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial does not specify if you need to stop your current medications. However, if your medication regimen is unstable or you frequently change or miss doses, you may not be eligible to participate.

Research has shown that treatments like AdiaVita, which use stem cells, are generally safe for people with kidney disease. In earlier studies, recipients reported few serious side effects, with common minor issues including mild pain at the injection site or temporary tiredness.

For glutathione, known for its antioxidant benefits, studies indicate it is usually safe when used as directed. Participants in past studies experienced only minor side effects, such as mild stomach upset or headaches.

Researchers are excited about AdiaVita combined with glutathione for chronic kidney disease because it represents a novel approach by utilizing stem cells. Most treatments for chronic kidney disease focus on managing symptoms and slowing progression with medications like ACE inhibitors or angiotensin receptor blockers. However, AdiaVita uses stem cells that may promote kidney repair and regeneration, offering potential for actual healing, rather than just management of the condition. This innovative mechanism could significantly change the way chronic kidney disease is treated, offering hope for more effective and comprehensive care.

Research has shown that stem cell treatments, like AdiaVita, have potential in aiding individuals with chronic kidney disease (CKD). In some studies, these treatments have maintained kidney function and reduced inflammation, a common issue in CKD. Other research has found that stem cell therapy can improve kidney health in individuals with related conditions, such as diabetic kidney disease. In this trial, one group of participants will receive a combination of stem cell treatment and glutathione, a substance that combats cell damage and might further aid kidney repair. Although more research is needed, these early findings suggest that AdiaVita combined with glutathione could support kidney function in CKD patients.¹⁶⁷⁸⁹